SecBot SecBot
8-K ·Filed Nov 3, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed13d 10h ago SEC0001062993-26-005723
8-K context-dependent: Items 7.01
Actionable Insight ▼ Bearish

The shareholder vote on the Mentari merger is the critical near-term catalyst. If approved, the $490M private placement could resolve the cash and Nasdaq compliance issues. If the merger fails, InMed faces imminent cash depletion and potential delisting.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.75
T+0 close · Nov 3, 2026 · via day close
Latest settled
−11.09%
T+5 · $1.56 · next T+20 in 16d
Vs SPY
−10.17%
α at T+5
Latest observation
+7.14%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $1.75entry
  2. T+1 · 12d ago −24.51%α −20.11% · $1.32
  3. T+5 · 6d ago −11.09%α −10.17% · $1.56
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals reported Q1 FY2027 results with a net loss of $2.33M, cash burn reducing cash to $1.09M (runway into mid-November), and shareholders' equity turning negative at -$1.20M. The company is pursuing a merger with Mentari Therapeutics (shareholder vote Nov 4) and has a Nasdaq compliance plan accepted through March 2027.

Key Facts

  • Net loss of $2,330,778 for Q1 FY2027 vs $1,726,899 in Q1 FY2026
  • Cash and cash equivalents fell to $1,094,488 from $2,194,413 at June 30, 2026
  • Shareholders' equity turned negative at -$1,199,396 vs $1,075,007 at June 30, 2026
  • Cash runway expected only into mid-November 2026
  • Nasdaq compliance plan accepted with deadline of March 15, 2027 to regain minimum $2.5M equity
  • Proposed merger with Mentari Therapeutics shareholder vote scheduled for November 4, 2026

Financial Impact

Cash burn of $1.1M in the quarter; negative equity of $1.2M; cash runway of approximately 2 weeks from filing date

cashshareholders' equitynet loss

Risk Factors

  • Cash runway only into mid-November 2026, creating existential risk if merger does not close
  • Negative shareholders' equity of $1.2M with Nasdaq minimum equity requirement of $2.5M
  • Merger with Mentari may not receive required shareholder approval
  • No revenue stream; continued operating losses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062993-26-005723
Document: form8k.htm0001062993-26-005723
Document: 0001062993-26-005723-index-headers.html0001062993-26-005723
Document: 0001062993-26-005723-index.html0001062993-26-005723
Document: 0001062993-26-005723.txt0001062993-26-005723

Track record

22 reports on INM

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +19.19% at T+5 after the Mar 20, 2026 report. 9 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bearish 6/10 Viewing Entry $1.75 Now $19.87 −1035.43% settles Dec 3
  5. Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
  6. Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
  7. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
  8. Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
  9. Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
  10. Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026